ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Quanterix Corporation

Quanterix Corporation (QTRX)

10.50
0.51
(5.11%)
Closed December 22 4:00PM
10.50
-0.01
(-0.10%)
After Hours: 5:30PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
10.50
Bid
9.88
Ask
14.00
Volume
547,647
9.87 Day's Range 10.75
9.94 52 Week Range 29.70
Market Cap
Previous Close
9.99
Open
9.87
Last Trade Time
Financial Volume
$ 5,612,352
VWAP
10.2481
Average Volume (3m)
384,989
Shares Outstanding
38,379,033
Dividend Yield
-
PE Ratio
-12.47
Earnings Per Share (EPS)
-0.84
Revenue
122.37M
Net Profit
-32.33M

About Quanterix Corporation

Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect p... Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Headquarters
Wilmington, Delaware, USA
Founded
-
Quanterix Corporation is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker QTRX. The last closing price for Quanterix was $9.99. Over the last year, Quanterix shares have traded in a share price range of $ 9.94 to $ 29.70.

Quanterix currently has 38,379,033 shares outstanding. The market capitalization of Quanterix is $383.41 million. Quanterix has a price to earnings ratio (PE ratio) of -12.47.

QTRX Latest News

Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and...

Quanterix Announces Receipt of Expected Notice from Nasdaq

Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.59-5.3201082055911.0911.519.9457961010.68358927CS
4-1.34-11.317567567611.8413.0059.9436219211.4580058CS
12-2.68-20.333839150213.1815.679.9438498912.34584991CS
26-3.01-22.279792746113.5116.749.9440918912.86371252CS
52-17.24-62.148521989927.7429.79.9439445816.5831545CS
156-31.04-74.723158401541.5444.866.3140521817.3011841CS
260-13.41-56.085319949823.9192.576.3134772926.70504886CS

QTRX - Frequently Asked Questions (FAQ)

What is the current Quanterix share price?
The current share price of Quanterix is $ 10.50
How many Quanterix shares are in issue?
Quanterix has 38,379,033 shares in issue
What is the market cap of Quanterix?
The market capitalisation of Quanterix is USD 383.41M
What is the 1 year trading range for Quanterix share price?
Quanterix has traded in the range of $ 9.94 to $ 29.70 during the past year
What is the PE ratio of Quanterix?
The price to earnings ratio of Quanterix is -12.47
What is the cash to sales ratio of Quanterix?
The cash to sales ratio of Quanterix is 3.3
What is the reporting currency for Quanterix?
Quanterix reports financial results in USD
What is the latest annual turnover for Quanterix?
The latest annual turnover of Quanterix is USD 122.37M
What is the latest annual profit for Quanterix?
The latest annual profit of Quanterix is USD -32.33M
What is the registered address of Quanterix?
The registered address for Quanterix is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Quanterix website address?
The website address for Quanterix is www.quanterix.com
Which industry sector does Quanterix operate in?
Quanterix operates in the LAB ANALYTICAL INSTRUMENTS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
$ 80.55
(8.54%)
281.23M

QTRX Discussion

View Posts
ziggy7796 ziggy7796 2 years ago
Nice bounce from yesterday's 56% drop!!!

Ziggy
👍️ 1
XenaLives XenaLives 5 years ago
NEUROLOGY
Simoa® is not just a better way to detect CNS biomarkers
It's a 1,000-times better way

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.



https://www.quanterix.com/therapeutic-areas/cns-biomarkers
👍️0
XenaLives XenaLives 6 years ago

QUANTERIX’ SIMOA TECHNOLOGY POWERS MORE THAN 85 PERCENT OF NEUROFILAMENT LIGHT BIOMARKER RESEARCH TO BE UNVEILED AT AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
Leading global neurology conference will feature 36 new Simoa-powered studies validating the use of Neurofilament light chain (Nf-L) as a potential diagnostic and prognostic biomarker for neurodegeneration

LEXINGTON, Mass.--(BUSINESS WIRE)--May 6, 2019-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology is the driving force behind 36 of the 42 – nearly 86 percent – Nf-L abstracts being presented at the American Academy of Neurology (AAN)’s Annual Meeting, taking place from May 4-10, 2019 in Philadelphia, PA. This year’s program represents a nearly four-fold increase in Nf-L research compared to last year, reinforcing the marker’s mounting value as a key indicator of neurodegenerative disease onset and progression.

“As the use cases for Nf-L grow, evidenced by the growing body of research presented at AAN, we believe that this biomarker is truly one of the most promising biomarkers for brain health with the power to completely transform the way diseases like Alzheimer’s, Multiple Sclerosis, Parkinson’s, and even brain injuries are diagnosed and treated,” said Kevin Hrusovsky, Chairman and CEO of Quanterix. “Nf-L has the ability to create new testing modalities for detection and treatment across numerous degenerative disease states, including some of the most difficult-to-detect conditions. Our Simoa technology helped researchers measure Nf-L accurately in blood for the first time, and it’s incredibly rewarding to see the continued impact of our technology on these and many other studies.”

This year’s AAN Annual Meeting will feature Nf-L abstracts that assess the viability of the biomarker as a reliable means to detect and monitor a range of neurodegenerative diseases in blood, including Alzheimer’s Disease, MS, ALS, spinal muscular atrophy and Huntington’s. In addition to evaluating the use of serum Nf-L as a comparable marker to traditional cerebral spinal fluid (CSF), presenters will speak to the marker’s drug development benefits for neurodegenerative clinical trials, which continue to face challenges and limitations based on using imaging or cerebrospinal fluid as endpoints. Furthermore, Nf-L is currently included in 46 active clinical trials in the US alone, demonstrating the degree to which its value for monitoring drug response has grown recently.

Quanterix’ Simoa platform is among the technologies proving integral to the study of serum Nf-L for these purposes in large part because it operates at a sensitivity level that is, on average, 1,000 times greater than traditional immunoassays. This dramatic improvement in sensitivity gives researchers unprecedented visibility into the presence of blood-based biomarkers suggestive of various neurological disorders. To date, the company’s technology has been utilized in more than 300 peer-reviewed studies, with more than 170 papers addressing neurological disorders specifically. Findings from this research demonstrate Simoa’s ability to potentially see disease progression earlier than imaging or CSF, improve treatment monitoring, and accelerate the delivery of more effective and safer drugs to market.

To learn more about Quanterix and its biomarker detection solutions, visit AAN Booth 1600. For more information on the AAN abstracts featuring Nf-L and Simoa, click here.

To learn more about Quanterix’ Nf-L assay, click here.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.



View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005487/en/

Source: Quanterix Corporation

PAN Communications
Lindsay Poole, 617-502-4300
quanterix@pancomm.com


http://ir.quanterix.com/news-releases/news-release-details/quanterix-simoa-technology-powers-more-85-percent-neurofilament
👍️0

Your Recent History

Delayed Upgrade Clock